Bernstein Harold 4

4 · Maze Therapeutics, Inc. · Filed Mar 12, 2026

AI-generated summary of this filing

Updated Mar 12, 2026

Maze Therapeutics (MAZE) CMO Harold Bernstein Exercises Options, Sells Shares

What Happened

Harold Bernstein, President, R&D & Chief Medical Officer of Maze Therapeutics, exercised options for 30,000 shares (code M) on 2026-03-10 by paying $10.42/share (cost $312,600) and sold a total of 30,000 shares (codes S) that same day, producing aggregate proceeds of about $1,513,560 (29,652 shares at a weighted $50.45 = $1,495,807; 348 shares at a weighted $51.02 = $17,753). The filing also reports a separate conversion/derivative line for 30,000 shares at $0.00 (reported as disposed) — see footnotes for vesting details.

Key Details

Transaction date: 2026-03-10; Form filed: 2026-03-12 (timely filing).
Sales pricing: reported weighted averages $50.45 (range $50.00–$50.99) and $51.02 (range $51.00–$51.09).
Exercise cost: 30,000 shares exercised at $10.42/share (total $312,600).
Reported proceeds from sales: ≈ $1,513,560.
Footnotes: sales were effected under a Rule 10b5-1 trading plan adopted Sept 29, 2025 (F1); weighted-average price ranges disclosed and available on request (F2, F3); option vesting schedule provided (F4).
Shares owned after transaction: not specified in the provided filing summary.

Context

This sequence shows an option exercise (derivative conversion) and near-immediate market sales of the resulting shares — a common pattern for covering exercise costs or taking liquidity rather than an explicit statement of sentiment. The 10b5-1 disclosure indicates at least some sales were preplanned under an approved trading plan. For full details (exact post-transaction holdings and the $0.00 derivative line), consult the complete Form 4 or contact the company’s SEC filings.

Form 4

Period: 2026-03-10

President, R&D & CMO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-10$10.42/sh+30,000$312,600→ 30,000 total
Sale
Common Stock
[F1][F2]
2026-03-10$50.45/sh−29,652$1,495,807→ 348 total
Sale
Common Stock
[F1][F3]
2026-03-10$51.02/sh−348$17,753→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-03-10−30,000→ 267,407 total
Exercise: $10.42Exp: 2032-10-26→ Common Stock (30,000 underlying)

Footnotes (4)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.09 per share, inclusive.
[F4]The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Signature

/s/ Courtney Phillips, as attorney-in-fact|2026-03-12

1 file